These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 3114198)
1. Characteristics of mouse thymocyte-derived, interleukin 2-activated killer cells and their precursors. Yagi H; Nishimura T; Hashimoto Y Jpn J Cancer Res; 1987 Jul; 78(7):721-8. PubMed ID: 3114198 [TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer (LAK) cells. III. Characterization of LAK precursors and susceptible target cells within the murine thymus. Ballas ZK; Rasmussen W J Immunol; 1987 Nov; 139(10):3542-9. PubMed ID: 3500221 [TBL] [Abstract][Full Text] [Related]
3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
4. Generation of lymphokine-activated killer cell activity from human thymocytes. Ramsdell FJ; Golub SH J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246 [TBL] [Abstract][Full Text] [Related]
5. The precursor cells of mouse lymphokine-activated killer (LAK) cells. Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y Thymus; 1987; 9(3):131-9. PubMed ID: 3495912 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of long-term cultured activated killer cells induced by anti-T3 antibody. Yun YS; Hargrove ME; Ting CC J Immunol; 1988 Aug; 141(4):1390-7. PubMed ID: 3260924 [TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989 [TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412 [TBL] [Abstract][Full Text] [Related]
10. Precursor phenotype of lymphokine-activated killer cells in the mouse. Salup RR; Mathieson BJ; Wiltrout RH J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370 [TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations. Ballas ZK; Rasmussen W; van Otegham JK J Immunol; 1987 Mar; 138(5):1647-52. PubMed ID: 2879870 [TBL] [Abstract][Full Text] [Related]
12. Properties of target molecule of murine lymphokine-activated killer (LAK) cells and the clones. Hashimoto Y; Kato K; Sato N; Yagi H; Yagita H; Nishimura T Princess Takamatsu Symp; 1988; 19():315-22. PubMed ID: 3077625 [TBL] [Abstract][Full Text] [Related]
13. Interferon-gamma is produced by activated immature mouse thymocytes and inhibits the interleukin 4-induced proliferation of immature thymocytes. Ransom J; Fischer M; Mosmann T; Yokota T; DeLuca D; Schumacher J; Zlotnik A J Immunol; 1987 Dec; 139(12):4102-8. PubMed ID: 3121729 [TBL] [Abstract][Full Text] [Related]
14. Cultured Lyt-2- L3T4- T lymphocytes from normal thymus or lpr mice express a broad spectrum of cytolytic activity. Budd RC; Cerottini JC; MacDonald HR J Immunol; 1986 Dec; 137(12):3734-41. PubMed ID: 3491147 [TBL] [Abstract][Full Text] [Related]
15. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties. Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186 [TBL] [Abstract][Full Text] [Related]
16. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. Ohnishi H; Lin KM; Chu TM Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759 [TBL] [Abstract][Full Text] [Related]
17. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity. Ting CC; Hargrove ME; Yun YS J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909 [TBL] [Abstract][Full Text] [Related]
18. Anti-Thy-1 plus complement-treated, cultured bone marrow cells resemble fetal thymocytes in killer cell function and marker expression. Hurwitz JL; McAndrew EC; Doherty PC J Immunol; 1986 Sep; 137(6):1757-63. PubMed ID: 2875109 [TBL] [Abstract][Full Text] [Related]